Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by SABBOBCATon Jan 16, 2021 11:00am
267 Views
Post# 32313191

Dubuc's comment on where shares went

Dubuc's comment on where shares wentIf true, I find Dubuc's comment about knowing shares went to long term holders to be disturbing. The banks they dealt with were already supporters, so their clients likely already had shares of TH. So if I were a client of syndicate (either retail or institutional). Why would I not sell my current TH shares at a profit and but the units to get warrants for free? This then floods the market with existing TH shares that are going to go to who knows where. This good of shares will need to be digested over time before the price settles a a fresh equilibrium. As we can see this equilibrium will be lower and kill any upward momentum their marketing efforts would generate in the short term. So while the units could very well go to strong hands, Dubuc's comment, if true, was nice and insulting to existing shareholders. This deal was a way to reward these banks and their clients at the expense of the rest of the shareholders. Terrible leadership and corporate governance allowed this to happen. This was a shady Quebec style move that warrants zero respect or credibility on the North American or Global stage. If you are a junior mining company, sure go for it, people expect that this stuff happens, but for a company striving to play in the global pharma space, this is appalling. The executive team and the board should be ashamed.
<< Previous
Bullboard Posts
Next >>